Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our discovery efforts have resulted in four approved products and we have partnered with leading pharmaceutical companies to bring these important medicines to patients worldwide. Exelixis continues to invest in the cabozantinib clinical development program in our efforts to maximize its potential through pivotal studies, including the COSMIC and CONTACT clinical trial programs. In addition, we continue to invest in expansion of our product pipeline through internal drug discovery activities and strategic business development opportunities.